Federated Hermes, Inc. Autolus Therapeutics PLC Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$4.2 - $13.0 $328,305 - $1.02 Million	-78,168 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.13 - $16.28 $29,127 - $42,604	2,617 Added 3.46%	78,168 $1.03 Million
Q3 2019 Nov 14, 2019	BUY	$9.79 - $16.72 $206,529 - $352,725	21,096 Added 38.74%	75,551 $938,000
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $78,444 - $162,343	5,195 Added 10.55%	54,455 $877,000
Q4 2018 Feb 13, 2019	BUY	$24.21 - $48.01 $55,997 - $111,047	2,313 Added 4.93%	49,260 $1.62 Million
Q3 2018 Nov 13, 2018	BUY	$20.86 - $33.33 $979,314 - $1.56 Million	46,947 New	46,947 $1.42 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.